McKesson Sees 2027 Profit Surpass Estimates on Oncology, Specialty Drug Strength
McKesson forecast 2027 profit slightly above consensus after beating Q1 profit estimates, driven by strength in oncology and specialty drug distribution. The company cited robust GLP-1 and biopharma services demand offset by soft medical-surgical trends.
1. First-Quarter Performance
McKesson reported stronger-than-expected first-quarter adjusted profit as oncology and specialty drug distribution growth drove margin expansion. The distributor saw robust GLP-1 therapy logistics and biopharma services growth while medical-surgical supply volumes lagged, tempering overall revenue gains.
2. 2027 Profit Outlook
The company forecasts fiscal 2027 profit slightly above consensus, citing continued strength in oncology and specialty drug distribution alongside sustained GLP-1 demand. Management plans to leverage biopharma services investments to offset softness in medical-surgical trends and support long-term margin improvement.